Tag: Patients
Search News
Prof John Gribben in BBC’s The Diagnosis Detectives
15th September 2020
Professor John Gribben, Lead for the Centre for Haemato-Oncology at Barts Cancer Institute and Consultant Haematologist at Barts Health NHS Trust, is part of a new BBC Two series called The Diagnosis Detectives. Professor Gribben is one of a panel of 12 of the UK’s leading medical experts who have been assembled to diagnose patients with life-changing symptoms that have puzzled other doctors and remained undiagnosed.
Read more
Biological clues in tissues surrounding breast tumours
9th September 2020
A new study has identified molecular characteristics in ‘normal-looking’ tissues surrounding breast tumours that may indicate whether breast cancer is likely to return following surgical removal of the tumour.
Read more
Proposed new surgery protocol for ovarian cancer
17th August 2020
For women at high risk of ovarian cancer, standard preventive practice is to offer removal of both the fallopian tubes and ovaries, but the surgery induces menopause in women who have not yet reached this stage of life. A proposed alternative two step surgical protocol, which delays the induced menopause caused by the removal of the ovaries, is highly acceptable to this premenopausal group of women.
Read more
Broadening cancer gene testing
21st July 2020
Screening entire populations for breast and ovarian cancer gene mutations could prevent millions more cancer cases across the world compared to current clinical practice, according to an international study led by Queen Mary University of London.
Read more
Covid-19 and blood cancer
3rd June 2020
One of the first studies to investigate the outcome of Covid-19 infection in patients with blood cancer has been conducted by clinical researchers from Barts Cancer Institute, Queen Mary University of London, and Barts Health NHS Trust.
Read more
Immunotherapy for advanced bladder cancer
29th May 2020
An immunotherapy drug called ‘avelumab’ has been shown to significantly improve survival in patients with the most common type of bladder cancer, according to results from a phase III clinical trial led by Professor Tom Powles.
Read more